Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (5388)	7/29/1998 10:36:00 AM
From: Bluegreen	Respond to of 9719

Little Richard: Bob has challenged you then and there on the Xoma board to an all out discussion of the science behind BPI and custom made derivatives thereof. We don't want to clutter up this board so are you going to show up or not? Come on Richy, Bob is all warmed up. My bet is you will chicken out but I'm hoping I am wrong! Remember no idle gossip about the company just the science.

To: Robert K. who wrote (5388)	7/29/1998 11:37:00 AM
From: scaram(o)uche	Respond to of 9719

Bob: I answered your question. I said "To answer your question directly...... I don't know". Prophylaxis of sepsis is a more promising ballpark than the venue for previous XOMA efforts, and, as I've said many times and IMO, the trials are well designed and conceived. Let's hope that the results of the trauma trial are positive. You want an answer outside of the context of the company/management, XOMA's current market cap, risk:reward ratio relative to other biotechs, etc. You now have such. I have long traded the issue with marked success, and I hope to continue to do such. Good luck. Rick